Retatrutide 5mg Peptide

Retatrutide 5mg is a triple receptor agonist research peptide supplied as a lyophilised powder for controlled laboratory investigation. The compound is designed to interact with three receptor pathways – GIP, GLP-1 and glucagon – making it an important subject within metabolic and receptor-signalling research.

• 5mg Retatrutide per vial
• High-purity research peptide
• Lyophilised powder in a sealed vial
• Suitable for laboratory and analytical research
• Batch documentation / COA available where applicable
• UK-based dispatch

For laboratory research use only. Not for human or veterinary consumption.

Retatrutide 5mg – Triple Agonist Research Peptide

Retatrutide 5mg provides a smaller-format option for laboratories investigating the activity of multi-receptor peptide compounds. Each vial contains 5mg of Retatrutide supplied in lyophilised form to support controlled storage, preparation and experimental handling.

Retatrutide is a synthetic peptide developed to demonstrate agonist activity across the GIP, GLP-1 and glucagon receptors. This three-pathway mechanism distinguishes it from compounds that primarily target one or two receptor systems and has made Retatrutide an increasingly studied molecule within metabolic research.

Retatrutide 5mg Key Specifications

Compound	Retatrutide
Strength	5mg per vial
Receptor activity	GIP / GLP-1 / glucagon triple agonist
CAS number	2381089-83-2
Molar mass	Approximately 4,731 g/mol
Form	Lyophilised powder
Packaging	Single sealed research vial
Intended use	Laboratory research only

Why Choose the Retatrutide 5mg Vial?

The 5mg format provides researchers with a lower-quantity option when a larger vial is unnecessary for the intended experimental design. It can be particularly useful for preliminary analytical work, small-scale laboratory investigations and research programmes comparing different quantities or concentrations of the same compound.

Using a smaller vial may also help laboratories manage research material efficiently when only limited quantities are required for a particular experimental programme.

Triple Receptor Agonist Research

One of the defining characteristics of Retatrutide is its activity across three receptor systems rather than a single pathway.

These include the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor.

The combined receptor profile has generated substantial scientific interest in Retatrutide as researchers investigate how simultaneous activation of multiple metabolic signalling pathways differs from single- and dual-receptor agonist compounds.

Purity & Quality Testing

Research peptides should be accompanied by appropriate analytical information so laboratories can evaluate the material being used in their experiments.

Where available for the supplied batch, a Certificate of Analysis (COA) provides relevant information relating to peptide identity, purity and analytical testing.

Researchers should always refer to the documentation associated with the specific batch rather than assuming that analytical results from one production batch automatically apply to another.

Storage & Laboratory Handling

Retatrutide 5mg should be stored according to the conditions stated on the product label and accompanying batch documentation.

The lyophilised material should be protected from unnecessary exposure to moisture, heat and direct light. Laboratories should follow their established handling, preparation and storage procedures when working with research peptides.

Appropriate laboratory technique and accurate record keeping are recommended to maintain sample traceability throughout an experimental programme.

Retatrutide 5mg – Frequently Asked Questions

What is Retatrutide 5mg?

Retatrutide 5mg is a research peptide supplied as a lyophilised powder containing 5mg of Retatrutide per vial. It is intended exclusively for laboratory and analytical research.

What receptors does Retatrutide target?

Retatrutide has been developed as a triple agonist with activity at the GIP, GLP-1 and glucagon receptors. This distinguishes it from single- and dual-receptor agonist compounds.

How is Retatrutide 5mg supplied?

The product is supplied as a measured quantity of lyophilised peptide in a sealed research vial. Researchers should check the individual product label and batch documentation for specifications relating to the supplied material.

Why choose a 5mg Retatrutide vial?

A 5mg vial provides a smaller quantity of material for laboratories that do not require higher-strength formats. It may be suitable for preliminary studies, analytical work or experimental programmes where smaller quantities are preferable.

Is a Certificate of Analysis available?

Where provided for the relevant production batch, a Certificate of Analysis can be used to review analytical information relating to the identity and purity of the supplied peptide.

Is Retatrutide an approved medicine?

Retatrutide remains an investigational compound. A research-grade Retatrutide product should not be presented as an authorised medicine or as a product intended to diagnose, prevent or treat disease.

Disclaimer: Retatrutide 5mg is supplied strictly for laboratory and research purposes. It is not a medicinal product and is not intended for human or veterinary consumption. It must not be used to diagnose, treat, cure or prevent any disease.